Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $51.25 and last traded at $49.73, with a volume of 159339 shares changing hands. The stock had previously closed at $49.41.
Gemini Therapeutics Price Performance
The firm has a market capitalization of $2.15 billion, a P/E ratio of -1.35 and a beta of -0.12. The firm has a fifty day simple moving average of $45.34 and a two-hundred day simple moving average of $45.44.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
See Also
- Five stocks we like better than Gemini Therapeutics
- What is the S&P/TSX Index?
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- Investing in Travel Stocks Benefits
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- The 3 Best Blue-Chip Stocks to Buy Now
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
